INSULIN Act of 2026

S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First

Client expense: $1,530,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

PBM Reform, transparency S. 1414, Expedited Access to Biosimilars Act - A bill to provide that clinical studies required for licensure of biological products as biosimilar shall not be required to include the assessment of immunogenicity, pharmacodynamics, or comparative clinical efficacy. S.4189 - INSULIN Act of 2026 - A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin. H.R.7895 - PBM Kickback Prohibition Act - A bill to prohibit kickbacks to pharmacy benefit managers.

Client expense: $300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advancing policies and programs to improve access to care and expand treatment options for individuals living with diabetes and obesity; Policy related to the use of Continuous Glucose Monitors and access to insulin; Insulin Act (S. 4189 / H.R. 3014); Diabetes Act (S. 4037); Drug pricing/PBM Reform; Medicare Diabetes quality measures; Medicare coverage of diabetes - related devices/technology, drugs, and care.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $1,240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

SAFE Drugs Act (H.R.6509/ S.3794); Diabetes Act (S. 4037) and competitive bidding program; INSULIN Act (H.R. 10227/ S. 4189); Diabetes foot health (H.R. 7905/H.R. 1616/S. 4070/ S. 1805); Childhood Diabetes Reduction Act (S. 5026); Special Diabetes Program Reauthorization (NIH and IHS); Appropriations for National Institutes of Health and Centers for Disease Control and Prevention; Issues related to insurance reform.

Client expense: $100,000 · Firm income: Not reported

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

H.R. 2102 Major Richard Star Act H.R. 2199 - Restore Protections for Dialysis Patients Act H.R. 4710 No Surprises Act Enforcement Act H.R. 8347, the Reinforcing Underserved, Rural, and Local (RURAL) Healthcare Act H.R. 9237 Take Care of Americas Veterans Act Hearing: Less Red Tape, More Opportunity: Unleashing American Workers and Job Creators Rep. Dingell heat safety letter and legislation S. 1032 Major Richard Star Act S. 2355 - Patients Deserve Price Tags Act S. 2420 - No Surprises Act Enforcement Act S. 4378 - Protecting American Taxpayers Act S. 4744 Take Care of Americas Veterans Act S.2420 No Surprises Act Enforcement Act S.4189 - INSULIN Act S.4742 - AI DATA Act S.J.Res. 198 to end WISeR demonstration program in Medicare S.J.Res.197 - CRA resolution to halt HHS ACA rule S.J.Res.198 - CRA resolution to halt the Wasteful and Inappropriate Service Reduction program Toxic Substance Control Act- Draft bills

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S.2276/ H.R. 3269; Eliminating Thickets to Improve Competition Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 S. 5586; Ensuring Accurate Payments to Specialty Pharmacies Act H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services H.R. 9645; Health Care Price Certainty for All Americans Act H.R. 10369; Net Effective Cost Transparency and Prescription Drug Affordability Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,203,049 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE

Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957); the Living Donor Protection Act (S.1552 and H.R. 4583); and legislation to clarify that organ donation surgery qualifies as a serious health condition for FMLA coverage (S. 1552, H.R. 4582). Comments on implementation of the Honor Our Living Donors Act changes to the Living Organ Donation Reimbursement Program. Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Support for xenotransplantation. Initiatives to improve chronic kidney disease early detection and management. S. 4189 and H.R. 10227, the "Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 (INSULIN Act). Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. H.R. 151, the "New Era of Preventing End-Stage Kidney Disease Act." Support for access to affordable, accessible health care, including Affordable Care Act enhanced premium tax credits.

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE, White House Office

Issues related to implementation of P.L. No: 119-21, One Big Beautiful Bill Act- Medicaid & SNAP cuts; Drug pricing/access to affordable medication; Health Workforce Training/Development; S. 4189, INSULIN Act of 2026

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Affordable Care Act and Extending Enhanced APTCs (H.R. 247; S. 46), Individual Market/ACA exchanges; Fraudulent Enrollments in Qualified Health Plans (S. 976, HR 2079), Behavioral Health, Employer-Provided Health Coverage; Surprise Billing (S. 2420, H.R. 4710); Cybersecurity; Health IT, Health Care Innovation, Transparency & PBMs (S. 891, H.R. 6703), PBM Compensation (H.R. 7895), Prescription Drugs (S. 1954, S. 1096, S.1040), Price Transparency (S. 2355, H.R. 9393, H.R. 9397, H.R. 9645, H.R. 9390), Prior Authorization (H.R. 9396), 340B, Insulin (S. 4189), Corporate Practice of Medicine, Anticompetitive Contracting (H.R. 6248, S. 4027).

Client expense: $670,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Use of provider-neutral and inclusive language in federal documents, forms, and surveys Reauthorization of the Child Nutrition Act Implementation of 42 USC 300gg-5(a) regarding provider non-discrimination by health plans Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Tobacco and vaping prevention and cessation Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 1197/S. 1562, PREEMIE Reauthorization Act H.R. 1435/S. 3714, Family-to-Family Reauthorization Act of 2025 H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 2472, Improving Newborns' Food and Nutrition Testing Safety (INFANTS) Act of 2025 H.R. 2493, Improving Care in Rural America Reauthorization Act of 2025 H.R. 3333, Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R. 3492, Protect Childrens Innocence Act H.R. 3624/S. 1924, Improving Mental Health Access for Students Act H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4262/S. 4110, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4340/S. 921, Tyler's Law H.R. 4564, Dillons Law H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 4725, Transparency, Readability, Understandability, Truth, and Helpfulness (TRUTH) in Labeling Act H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 5469/S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 5582, Patients Deserve Price Tags Act H.R. 6088/S. 3281, Restoring Food Security for Families & Farmers Act of 2025 H.R. 6121/S. 2303, Promoting Physical Activity for Americans Act H.R. 6252, Food Assurance and Security Act H.R. 6396, Kid Providing Resources for Optimal Outcomes against Fatalities (Kid PROOF) Act of 2025 H.R. 6561, PREVENT HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act H.R. 6844, Tobacco TRACE Act H.R. 6845/S. 3569, S.T.O.P. Illegal Vaping Act H.R. 6945/S. 4242, Supporting Pregnant and Parenting Women and Families Act H.R. 7092/S. 4061, Raising Awareness for Youth Suicide (RAYS) Prevention Act H.R. 7567, Farm, Food, and National Security Act of 2026 H.R. 7757, Kids Internet and Digital Safety (KIDS) Act H.R. 7867, Infant Formula Safety Modernization Act of 2026 H.R. 7875, Providing Opportunities for Individuals in Need of Treatment and Support (POINTS) Act H.R. 7973, Momnibus Act H.R. 8081/S. 4202, Mental Health Access and Provider Support Act H.R. 8089/S. 4186, Perinatal Workforce Act H.R. 8163, Provider Reimbursement Stability Act H.R. 8201, Expanding Community Access to Health Services Act H.R. 8209, School-Based Health Centers Reauthorization Act of 2026 H.R. 8385, Food Labeling Modernization Act of 2026 H.R. 8425, Strengthening the Vaccines for Children Program Act of 2026 H.R. 8429, Baby Food Safety Act of 2026 H.R. 8521/S. 4387, Protect Moms from Domestic Violence Act H.R. 8657, Campus Lifeline Act H.R. 9257/S. 4754, Primary and Behavioral Health Care Access Act H.R. 9393, Lower Costs, More Transparency Act of 2026 S. 222/H.R. 649, Whole Milk for Healthy Kids Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 S. 1885, Stop the Scroll Act S. 1482, National Nursing Workforce Center Act of 2025 S. 1599/H.R. 6394, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2169, Rural Hospital Cybersecurity Enhancement Act S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3199, 988 Lifeline Location Improvement Act of 2025 S. 3315, Health Care Cybersecurity and Resiliency Act of 2025 S. 3386, Health Care Freedom for Patients Act of 2025 S. 3402, Ensuring Excellence in Mental Health Act S. 3799, Healthy Start Reauthorization Act of 2026 S. 3853, End the Vaccine Carveout Act S. 4088, Welcome Back to the Health Care Workforce Act S. 4141, Rural Hospital Revitalization Act S. 4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

Health care policy; Telehealth; H.R. 9504 Tax Exempt Hospital Transparency Act, 340B; Clinical Trials; Artificial intelligence; Pediatric health care workforce training; AHEAD Model; S.4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now Act, Insulin afforability and access

Client expense: $350,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 90 - Health Coverage Choice Act - Rep. Biggs, Andy - Duration of STLDHI plans H.R. 114 - Responsible Path to Full Obamacare Repeal Act - Rep. Biggs, Andy - ACA repeal H.R. 247 - Health Care Affordability Act - Rep. Underwood, Lauren - ACA tax credit extension H.R. 267 - Health Care Price Transparency Act - Rep. Davidson, Warren - Hospital and insurer transparency requirements H.R. 639 - Doctor Knows Best Act - Rep. Van Drew, Jefferson - Commercial market prior authorization H.R. 957 - Parity Enforcement Act - Rep. Norcross, Donald - Penalties for mental health parity violations H.R. 1385 - DOC Access Act - Rep. Carter, Earl Buddy - Rate setting for dental and optometric services H.R. 1397 - Increasing Access to Dental Insurance Act - Rep. Miller-Meeks, Mariannette - Standalone dental plans H.R. 1776 - New Health Options Act - Rep. Palmer, Gary - ACA reinsurance H.R. 2079 - Insurance Fraud Accountability Act - Rep. Ross, Deborah - fraudulent ACA enrollments H.R. 2199 - Restore Protections for Dialysis Patients Act - Rep. Kelly, Mike - ESRD coverage H.R. 2553 - Capping Prescription Costs Act - Rep. Horsford, Steven - Prescription cost-sharing H.R. 2554 - Lower Drug Costs for Families Act - Rep. Horsford, Steven - Commercial market drug rebates H.R. 2636 - Making Insulin Affordable for All Children Act - Rep. Landsman, Greg - Commercial market insulin cost-sharing H.R. 3020 - Addressing Anti-Competitive Health Care Contract Clauses Act - Rep. Spartz, Victoria - Study on anti-competitive contracting H.R. 3527 - Bridge to Medicaid Act - Rep. Sewell, Terri - ACA subsidies for non-Medicare expansion states H.R. 3701 - Family Vaccine Protection Act - Rep. Pallone, Frank - ACIP codification and vaccine coverage H.R. 4406 - State-Based Universal Health Care Act - Rep. Khanna, Ro - State-based universal health care H.R. 4710 - No Surprises Act Enforcement Act - Rep. Murphy, Greg - Surprise billing penalties for noncompliance by health insurers H.R. 5145 - Bipartisan Premium Tax Credit Extension Act - Rep. Kiggans, Jennifer - Temporary extension of ACA enhanced premium tax credits H.R. 5509 - Safe Step Act - Rep. Allen, Rick - Step therapy requirements H.R. 5582 - Patients Deserve Price Tags Act - Rep. James, John - Hospital and insurer price transparency requirement H.R. 6171 - ACA Copay CAP Act of 2025 - Rep. Auchincloss, Jake - establish out of pocket limit on prescription drugs H.R. 6248 - Healthy Competition for Better Care Act - Rep. Arrington, Jodey - ban anticompetitive terms in contracts, promote higher quality, lower cost care H.R. 6703 - Lower Health Care Premiums for All Americans Act - Rep. Miller-Meeks, Mariannette - amend ERISA to lower premiums H.R. 7023 - Affordable CHOICE Act - Rep. Schakowsky, Janice - public option under ACA H.R. 7164 - Capping Costs for Consumers Act - Rep. Schrier, Kim - ACA cost-sharing reductions H.R. 8270 - Every Dollar Counts Act - Rep. Murphy, Greg - Requirements for deductibles and MOOP to include expenditures for DTC prescriptions H.R. 8684 - Transparency in Billing Act - Rep. Foxx, Virginia - Transparency enforcement H.R. 9393 - Lower Costs, More Transparency Act - Rep. Guthrie, Brett - Healthcare price transparency S. 46 - Health Care Affordability Act - Sen. Shaheen, Jeanne - ACA tax credit extension S. 729 - Hospital Transparency Compliance Enforcement Act - Sen. Kennedy, John - Hospital price transparency requirements S. 864 - HELP Copays Act - Sen. Marshall, Roger - Cost-sharing requirements S. 976 - Insurance Fraud Accountability Act - Sen. Wyden, Ron - fraudulent ACA enrollments S. 2355 - Patients Deserve Price Tags Act - Sen. Marshall, Roger - Hospital and insurer price transparency requirements S. 2420 - No Surprises Act Enforcement Act - Sen. Marshall, Roger - Surprise billing penalties for noncompliance by health insurers S. 2824 - A bill to amend the Internal Revenue Code of 1986 to extend the temporary enhanced premium tax credits - Sen. Murkowski, Lisa - Temporary extension of ACA enhanced premium tax credits S. 2903 - Safe Step Act - Sen. Murkowski, Lisa - Step therapy requirement S. 3599 - Affordable CHOICE Act - Sen. Whitehouse, Sheldon - public option under ACA S. 3990 - PrEP Access and Coverage Act - Sen. Smith, Tina - Coverage requirements for HIV services S. 4189 - INSULIN Act - Sen. Collins, Susan - Insulin cost-sharing caps S. 4512 - Affordable Insulin Now Act - Sen. Kennedy, John - Insulin cost-sharing caps Issues related to implementation rule implementing the No Surprises Act prohibiting surprise medical bills; transparency report requirements; parity in mental health benefits; ERISA preemption; paperless delivery for health plan disclosures; Unauthorized Enrollments/Unauthorized Plan Switching; ACA Tax Credits (Inflation Reduction Act); final rule on Section 1557 of the ACA and its impact on Medigap plans; ACA Marketplace Enrollment and Agents and Brokers; Waste Fraud and Abuse; Vaccine Coverage; Preventative Services Coverage; the Advanced Explanation of Benefits; coverage of weight loss drugs; Transparency in Coverage; No Surprises Act; ACA Marketplace Integrity; ACA Enhanced Tax Credits; Prior Authorization; affordability; and health savings accounts.

Client expense: $3,010,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.1637/H.R 7871; Medicaid VBPs for Patients Act S. 4323/ H.R. 8143; Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026 S. 2355/H.R. 5582; Patients Deserve Price Tags Act S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 1041; Affordable Prescriptions for Patients Act S. 1095; Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act S. 1096; Preserve Access to Affordable Generics and Biosimilars Act S. 1097; Interagency Patent Coordination and Improvements Act of 2025 S. 1414; Expedited Access to Biosimilars Act S. 2617; Reducing Drug Prices for Seniors Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3345; PBM Price Transparency and Accountability Act S. 3349; PBM Disclosure Act S. 3549; PBM Fiduciary, Accountability, Integrity, and Reform Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 2214; Delinking Revenue from Unfair Gouging Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 4570; Interagency Patent Coordination and Improvements Act of 2025 H.R. 6609; Pharmacists Fight Back Act in Medicare and Medicaid H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 6837; To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services oSec. 6702- Full Rebate Pass Through to Plans H.R. 7895; PBM Kickback Prohibition Act H.R. 8324; Great American Healthcare Plan H.R. 9228; Health Data Access, Transparency, and Affordability Act of 2026 H.R. 9486; Health Data Access, Transparency and Affordability Act H.R. 9117; Clear Healthcare Expense Cost Knowledge Act H.R. 9393; Lower Cost, More Transparency Act of 2026 Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE, Small Business Administration (SBA)

S. 2426/H.R. 3164; Ensuring Community Access to Pharmacist Services Act S.4509/ H.R. 8779; Patients Before Monopolies Act S. 526; Pharmacy Benefit Manager Transparency Act S. 882; Patients Before Middlemen Act S. 927; Protecting Pharmacies in Medicaid Act S. 2800; Pharmacy and Medically Underserved Areas Enhancement Act S. 3822; Break Up Big Medicine Act S. 4189; INSLUN Act of 2026 H.R. 1244; Reducing Drug Prices for Seniors Act H.R. 4317; PBM Reform Act H.R. 4409; Fair Pharmacies for Federal Employees Act H.R. 6610; Pharmacists Fight Back Act in the Federal Employees Health Benefits Program H.R. 7148; Consolidated Appropriations Act of 2026 oSec. 6233- Any Willing Pharmacy oSec 6224- Medicare Delinking oSec. 6701- Oversight of PBM Services Implementation of the Inflation Reduction Act of 2022, P.L. 169- Provisions on Medicare Part D modernization and drug price negotiation, and the implementation of the Consolidated Appropriations Act of 2026 (P.L. 119-75)

Client expense: $3,282,990 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Urged Congress to oppose any legislation fast-tracking permitting and development of data centers. Urged Congress to fully fund the EPAs environmental justice programs. Supported H.R. 6815, the Environmental Justice Screening Tool Act. Supported S.3529, the Public Health Air Quality Act. Supported S.3928, the Standardized Calculation of Operational Polluting Emissions (SCOPE) Act of 2026. Supported S.4189, the Youth Climate Leadership Act. Opposed the EPAs proposed Common Sense Approach to Chemical Accident Prevention rule. Opposed the EPAs 2 year delay of light duty vehicle criteria pollutant standards. Supported H.Res.1245 Recognizing the importance of the Greenhouse Gas Reporting Program to protect the United States scientific integrity, public health, environment, and economic growth.

Client expense: $230,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

S. 4189 - the INSULIN Act; S. 4612/H.R. 9000 - the SCREEN For T1D Act; S. 4612, the SCREEN for T1D Act; H.R. 5467 - the Patient Access to Autoimmune Treatments Act; S. 8270/H.R. 8018 - the ISLET Act; Issues pertaining to cell and gene therapies; Issues pertaining to C-peptide; Issues pertaining to NIH research; Issues pertaining to Special Diabetes Program.

Client expense: $220,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S.4189 (INSULIN Act), H.R.1492, S.832 (EPIC Act); Medicare drug price negotiation improvement and expansion; Medicare drug price negotiation delay periods and exemptions; drug prices, S.2276, H.R.3269 (ETHIC Act), H.R.6485, S.43 Skinny Labels, Big Savings Act, patent abuse reform, Prescription Drug Access and Affordability Act, TrumpRx, Medicare drug price negotiation delay periods and eligibility , S.1941 Cure Hepatitis C Act , global health, PEPFAR funding, USAID funding, global access to medicines, S.1040 Drug Competition Enhancement Act S. 1095 Stop STALLING Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act, S.1941 Cure Hepatitis C Act ,

Client expense: $99,577 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $990,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1097 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Sen. Durbin, Richard J. [D-IL] H.R.4570 - Interagency Patent Coordination and Improvement Act of 2025 To amend title 35, United States Code, to establish an interagency task force between the United States Patent and Trademark Office and the Food and Drug Administration for purposes of sharing information and providing technical assistance with respect to patents, and for other purposes. Sponsor: Rep. Neguse, Joe [D-CO-2] S.2658 - Medication Affordability and Patent Integrity Act To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office. Sponsor: Sen. Hassan, Margaret Wood [D-NH] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.43 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Sen. Hickenlooper, John W. [D-CO] H.R.6485 - Skinny Labels, Big Savings Act To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. Sponsor: Rep. Cline, Ben [R-VA-6] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $20,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, White House Office

Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.3014 - Ensuring Timely Access to Generics Act of 2025 To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1302 - Increasing Transparency in Generic Drug Applications Act To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.1843 - Increasing Transparency in Generic Drug Applications Act To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R.7895 - PBM Kickback Prohibition Act To amend section 408 of the Employee Retirement Income Security Act of 1974 to prohibit kickbacks to pharmacy benefit managers. Sponsor: Rep. Allen, Rick W. [R-GA-12] H.R. 6837 - PBM FAIR Act To amend the Employee Retirement Income Security Act of 1974 to ensure that pharmacy benefit managers are considered fiduciaries, and for other purposes. Sponsor: Rep. Auchincloss, Jake [D-MA-4] H.R.3164 - Ensuring Community Access to Pharmacist Services Act To amend title XVIII of the Social Security Act to provide pharmacy payment of certain services. Sponsor: Rep. Smith, Adrian [R-NE-3] S.4189 - INSULIN Act of 2026 To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Sponsor: Sen. Shaheen, Jeanne [D-NH]

Client expense: $276,347 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PBM Reform, transparency H.R. 6703 - Lower Health Care Premiums for All Americans Act - A bill to ensure access to affordable health insurance. S.4189 - INSULIN Act of 2026 - A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin. H.R.7895 - PBM Kickback Prohibition Act - A bill to prohibit kickbacks to pharmacy benefit managers.

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Advancing policies and programs to improve access to care and expand treatment options for individuals living with diabetes and obesity; Policy related to the use of Continuous Glucose Monitors and access to insulin; Insulin Act (S. 4189 / H.R. 3014); Diabetes Act (S. 4037); Drug pricing/PBM Reform.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to implementation of P.L. No: 119-21, One Big Beautiful Bill Act - Medicaid & SNAP cuts; Drug pricing/access to affordable medication; Health Workforce Training/Development; Renewal of the ACA premium subsidies; S. 4189, INSULIN Act of 2026

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation and policies relating to: Potential changes in authorizations for nurse education, workforce, and research programs as a result of workforce reductions and reorganization of agencies and programs within the Department of Health and Human Services Policies related to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, child vaccine recommendations and schedule, the Vaccines For Children Program, and the Vaccine Injury Compensation Fund Cancellation of federal nursing workforce grants Adoption of recommendations of the National Academy of Medicine report, The Future of Nursing 2020-2030: Charting a Path to Achieve Health Equity Provisions of the Patient Protection & Affordable Care Act (P.L. 111-148) Use of provider-neutral and inclusive language in federal documents, forms, and surveys Reintroduction of the Primary and Behavioral Health Care Access Act Reauthorization of the Child Nutrition Act Implementation of 42 USC 300gg-5(a) regarding provider non-discrimination by health plans Policies affecting nurse practitioner education and workforce Definition, evaluation and enforcement of essential health benefits and provider network adequacy Mental health services and violence prevention Tobacco and vaping prevention and cessation Implementation of provisions of the One Big, Beautiful Bill Act (PL 119-21) H.R. 1197/S. 1562, PREEMIE Reauthorization Act H.R. 1435/S. 3714, Family-to-Family Reauthorization Act of 2025 H.R. 1627, Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) Act H.R. 1735/S. 779, Early Action and Responsiveness Lifts Youth Minds (EARLY Minds) Act H.R. 1834, Breaking the Gridlock Act H.R. 1909/S. 2621, Preventing Maternal Deaths Act H.R. 2223, Building Capacity for Care Act H.R. 3333, Magnifying Opportunities to Recruit and Educate (MORE) Nurses Act H.R. 3492, Protect Childrens Innocence Act H.R. 3701, Family Vaccine Protection Act H.R. 3884/S. 2011, Telemental Health Care Access Act H.R. 4262/S. 4110, Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act H.R. 4340/S. 921, Tyler's Law H.R. 4564, Dillons Law H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025 H.R. 5145, Bipartisan Premium Tax Credit Extension Act H.R. 5434/S. 2826, 988 LGBTQ+ Youth Access Act of 2025 H.R. 5469/S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 5629, To provide that the HHS final rule titled Medications for the Treatment of Opioid Use Disorder (except the portion relating to accreditation of opioid treatment programs) shall have no force or effect H.R. 6088/S. 3281, Restoring Food Security for Families & Farmers Act of 2025 H.R. 6252, Food Assurance and Security Act H.R. 6396, Kid Providing Resources for Optimal Outcomes against Fatalities (Kid PROOF) Act of 2025 H.R. 6561, PREVENT HPV Cancers Act of 2025 H.R. 6703, Lower Health Care Premiums for All Americans Act H.R. 6844, Tobacco TRACE Act H.R. 6845/S. 3569, S.T.O.P. Illegal Vaping Act H.R. 6945/S. 4242, Supporting Pregnant and Parenting Women and Families Act H.R. 7092, Raising Awareness for Youth Suicide (RAYS) Prevention Act H.R. 7567, Farm, Food, and National Security Act of 2026 H.R. 7757, Kids Internet and Digital Safety (KIDS) Act H.R. 7973, Momnibus Act H.R. 8089/S. 4186, Perinatal Workforce Act S. 222/H.R. 649, Whole Milk for Healthy Kids Act of 2025 S. 266/H.R. 929, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act S. 272, Protect Infant Formula from Contamination Act S. 278, Kids Off Social Media Act S. 705, Innovations in Pediatric Drugs Act S. 836/H.R. 6291, Children and Teens Online Privacy Protection Act (COPPA 2.0) S. 891, Bipartisan Health Care Act S. 1157/H.R. 2319, Women and Lung Cancer Research and Preventive Services Act of 2025 S. 1885, Stop the Scroll Act S. 1261, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2025 S. 1482, National Nursing Workforce Center Act of 2025 S. 1599/H.R. 6394, Midwives for Maximizing Optimal Maternity Services (MOMS) Act of 2025 S. 1748/H.R. 6484, Kids Online Safety Act S. 1874/H.R. 3593, Title VIII Nursing Workforce Reauthorization Act of 2025 S. 2169, Rural Hospital Cybersecurity Enhancement Act S. 2857/H.R. 5448, Protecting Free Vaccines Act S. 2954, Health Care Workforce Expansion Act of 2025 S. 3199, 988 Lifeline Location Improvement Act of 2025 S. 3315, Health Care Cybersecurity and Resiliency Act of 2025 S. 3386, Health Care Freedom for Patients Act of 2025 S. 3853, End the Vaccine Carveout Act S. 4088, Welcome Back to the Health Care Workforce Act S. 4189, Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act

Client expense: Not reported · Firm income: $24,000

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE

S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 S. 3064 - the Relief of Chronic Disease Pain Act of 2026 S. 4189 - the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026 H.R. 5467 - the Patient Access to Autoimmune Treatments Act S. 3105 / H.R. 8018 - the Increase Support for Life-saving Endocrine Transplantation Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to NIH/FDA funding Issues pertaining to screening and early detection

Client expense: $280,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.

Client expense: Not reported · Firm income: Not reported

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE

Issues related to implementation of P.L. No: 119-21, One Big Beautiful Bill Act - Medicaid & SNAP cuts; Drug pricing/access to affordable medication; Health Workforce Training/Development; Renewal of the ACA premium subsidies; S. 4189, INSULIN Act of 2026

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE